PMID- 26728234
OWN - NLM
STAT- MEDLINE
DCOM- 20160929
LR  - 20181202
IS  - 1540-8183 (Electronic)
IS  - 0896-4327 (Linking)
VI  - 29
IP  - 1
DP  - 2016 Feb
TI  - Clinical Outcomes of Bioresorbable Scaffold in Coronary Artery Disease: A 
      Systematic Literature Review.
PG  - 57-69
LID - 10.1111/joic.12260 [doi]
AB  - OBJECTIVES: We aim to perform a systematic literature review on all studies 
      reporting the clinical outcomes of the use of bioresorbable scaffolds (BRS) in 
      different settings of coronary artery disease (CAD). BACKGROUND: BRS are designed 
      to provide early support of the vessel wall postangioplasty, deliver 
      antiproliferative agents to prevent excessive hyperplastic healing responses and 
      finally "disappear" when no longer required. Emerging data have provided evidence 
      of their use in specific clinical scenarios. METHODS: A comprehensive literature 
      search was performed by 2 independent reviewers utilizing MEDLINE, EMBASE, and 
      Cochrane Library databases. The only 2 CE marked BRS: everolimus-eluting 
      Bioresorbable vascular scaffold ABSORB BVS and the myolimus-eluting DESolve 
      Bioresorbable Coronary Scaffold (BCS) System were included. RESULTS: The studies 
      were categorized into: ST elevation myocardial infarction (STEMI), stable CAD, 
      and "all-comers" group. Thirty-one studies were included; 8 in STEMI patients 
      (all ABSORB), 15 in stable CAD patients. In the STEMI group (n = 606), acute 
      procedural success ranged from 96% to 100%, cardiac mortality 0-9.1%, recurrent 
      MI and stent thrombosis rates were 0-4.3%. In the stable CAD group, the 13 ABSORB 
      studies (n = 3259) demonstrated cardiac mortality rate of 0-0.6%, recurrent MI 
      rate 0-4.5%, and stent thrombosis rate 0-4.3% CONCLUSIONS: Current clinical data 
      suggest the BRS, especially the ABSORB BVS, may represent a reasonable 
      alternative to DES in uncomplicated coronary anatomy.
CI  - (c) 2015, Wiley Periodicals, Inc.
FAU - Keh, Yann Shan
AU  - Keh YS
AD  - Department of Cardiology, National Heart Centre Singapore, Singapore.
FAU - Yap, Jonathan
AU  - Yap J
AD  - Department of Cardiology, National Heart Centre Singapore, Singapore.
FAU - Yeo, Khung Keong
AU  - Yeo KK
AD  - Department of Cardiology, National Heart Centre Singapore, Singapore.
AD  - Duke-NUS Graduate Medical School, Singapore.
FAU - Koh, Tian Hai
AU  - Koh TH
AD  - Department of Cardiology, National Heart Centre Singapore, Singapore.
FAU - Eeckhout, Eric
AU  - Eeckhout E
AD  - Division of Cardiology, Centre Hospitalier Universitaire Vaudois, Lausanne, 
      Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20160105
PL  - United States
TA  - J Interv Cardiol
JT  - Journal of interventional cardiology
JID - 8907826
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Absorbable Implants
MH  - Aged
MH  - *Angioplasty/instrumentation/methods
MH  - Antineoplastic Agents/pharmacology
MH  - Coronary Artery Disease/*surgery
MH  - Everolimus/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Sirolimus/*pharmacology
MH  - *Tissue Scaffolds
MH  - Treatment Outcome
EDAT- 2016/01/06 06:00
MHDA- 2016/09/30 06:00
CRDT- 2016/01/06 06:00
PHST- 2016/01/06 06:00 [entrez]
PHST- 2016/01/06 06:00 [pubmed]
PHST- 2016/09/30 06:00 [medline]
AID - 10.1111/joic.12260 [doi]
PST - ppublish
SO  - J Interv Cardiol. 2016 Feb;29(1):57-69. doi: 10.1111/joic.12260. Epub 2016 Jan 5.